EUVIMEDEUVIMED entdecken
Crossref

Real-World Experience in the Management of Chronic Myeloid Leukemia Patients Focused on Tyrosine Kinase Inhibitors Intolerance and Health-Related Quality of Life

Joon Ho Moon, Hee Jeong Cho, Dong Won Baek, Juhyung Kim, Young Eun Jang, Yunji Lee, Joon Ho Moon, Sang Kyun Sohn

Acta Haematologica · 10.01.2025 · 148 (6) · 708-721

DOI: 10.1159/000542562 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Haematologica, online erschienen am 10.01.2025. Verfasst von Joon Ho Moon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Kore…. Hauptthemen laut MEDLINE: Quality of Life, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aimed to analyze the survival outcomes and adverse events (AEs) associated with the long-term use of tyrosine kinase inhibitors (TKIs) and to assess health-related quality of life (HRQoL) in patients with chronic myeloid leukemia (CML).

Methods

Medical records of 345 patients with CML treated with at least one type of TKI were retrospectively reviewed.

Results

No significant differences in survival were observed based on the number of different TKIs the patients received (p = 0.301) or the sequence of TKIs used (p = 0.770). Among 182 patients treated with nilotinib, 25 experienced cardiovascular events (CVEs). After 10 years of nilotinib treatment, CVEs occurred in 55.2% of patients with ≥2 vascular risk factors. Pleural effusion was observed in 27 of 78 dasatinib-treated patients. In terms of HRQoL, patients treated with nilotinib generally reported higher satisfaction levels than did those treated with imatinib or dasatinib. When stratified by age or duration of TKI treatment, patients aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsHumansMiddle AgedMaleFemaleAgedAdultRetrospective StudiesDasatinibAged, 80 and overPyrimidinesTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

Adverse eventsChronic myeloid leukemiaHealth-related quality of lifeTyrosine kinase inhibitors

Substanzen

Protein Kinase InhibitorsnilotinibDasatinibPyrimidinesTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
  • Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea, posgary@gmail.com.

Zitieren

APA

Moon, J. H., Cho, H. J., Baek, D. W., Kim, J., Jang, Y. E., Lee, Y., Moon, J. H., & Sohn, S. K. (2025). Real-World Experience in the Management of Chronic Myeloid Leukemia Patients Focused on Tyrosine Kinase Inhibitors Intolerance and Health-Related Quality of Life. Acta Haematologica, 148(6), 708-721. https://doi.org/10.1159/000542562

Vancouver

Moon JH, Cho HJ, Baek DW, Kim J, Jang YE, Lee Y, et al. Real-World Experience in the Management of Chronic Myeloid Leukemia Patients Focused on Tyrosine Kinase Inhibitors Intolerance and Health-Related Quality of Life. Acta Haematologica. 2025;148(6):708-721. doi:10.1159/000542562

BibTeX
@article{Moon2025,
  author = {Moon, Joon Ho and Cho, Hee Jeong and Baek, Dong Won and Kim, Juhyung and Jang, Young Eun and Lee, Yunji and Moon, Joon Ho and Sohn, Sang Kyun},
  title = {Real-World Experience in the Management of Chronic Myeloid Leukemia Patients Focused on Tyrosine Kinase Inhibitors Intolerance and Health-Related Quality of Life},
  journal = {Acta Haematologica},
  year = {2025},
  volume = {148},
  number = {6},
  pages = {708--721},
  doi = {10.1159/000542562}
}
Kostenlos starten →